Servier challenges Mediator death figures
This article was originally published in Scrip
The French company Servier has taken issue with the methodology used by researchers in a recent study to estimate the probable number of deaths and hospitalisations resulting from the use of its antidiabetic/anorectic drug Mediator (benfluorex), saying that the figures do not correspond to available pharmacovigilance data.
You may also be interested in...
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.